Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mSIRK is a cell-permeable, myristoylated peptide that serves as a direct and specific activator of G-protein βγ (Gβγ) subunits. It is primarily utilized as a pharmacological research tool to investigate Gβγ-mediated signaling pathways independently of G-protein-coupled receptor (GPCR) activation. By binding to Gβγ subunits, mSIRK induces the dissociation of the Gαβγ heterotrimer, thereby triggering downstream effectors such as phospholipase C (PLC) and stimulating calcium influx from the extracellular space. In oncological research, particularly melanoma, mSIRK has been demonstrated to inhibit Epac-induced cell migration by modulating intracellular calcium dynamics and crosstalking with calmodulin-dependent pathways.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mSIRK.